Area of Purification Workshop
Hangzhou Biotest Biotech Co., Ltd. – a National High-tech Enterprise, is a professional manufacturer specializing in medical in vitro diagnostic assays and reagents,instrument research and development, and world-class sales and service. Biotest was established in 2008 with headquarters located in the natural scenic Eco-Industrial Park Yuhang District of Hangzhou city. Our flagship facility consists of an area of 85,000 square meters with registered capital of 106 million RMB.
Hangzhou Biotest Biotech Co., Ltd. supplies major IVD categories: fertility health, drug testing/toxicology, infectious disease identification, tumor marker detection and cardiac marker monitoring. Biotest harnesses the world-leading technologies of bioengineering by using gene recombinant antigens, synthetic antigens, mono-specific antibodies and polyclonal antibodies combined with latex and colloidal metal particles on immuno-chromatographic assay scaffold to accomplish our test development goals.
Biotest’s mission is to “provide customers with accurate, convenient and affordable medical test products.” Our elite employees possess the talent and prowess to drive the accelerated yet sustainable development of our enterprises. Over the years, Biotest has been steadfast in adhering to the principle of fostering healthy lives and is committed to funding the constant innovation required to continue our goal of overall wellness for mankind.
In 2015, Biotest embarked on the new journey of strategic global deployment by acquiring the American company Advin Biotech, Incorporated. This event marked our resolve towards penetrating the highly coveted American market. Advin Biotech is FDA registered and specializes in toxicology products including single drug combination and multiple drug combination detection kits. The company provides the most comprehensive drug detection tests for the American and global drug-testing markets including employee screening, medical diagnostics, judicial compliance and military testing.
Won the title of "National High-tech Enterprise"
Approved by the Municipal Development and Reform Commission to become a "Key Enterprise in the Health Industry of Zhejiang Province"
The "YE Plan" project passed the acceptance check of Hangzhou Science and Technology Bureau
Successfully acquired Advin Biotechnology Co., Ltd.
Complete the shareholding system transformation
7 products have been approved by China cFDA
2 products have been approved by China NMPA
Biotest is one of the manufacturers with a relatively complete variety of POCT diagnostic reagents in the world. Relying on strong independent innovation and management capabilities, Biotest has established a rapid immunodiagnosis platform, a POCT application technology platform, a biological core raw material technology platform, an automated production technology platform and other industrial technology platforms. On this basis, it has independently researched and developed a technology platform that includes reproduction Hundreds of products in five major product series, including health testing, drug abuse (drug) testing, infectious disease testing, tumor marker testing, and myocardial marker testing, are widely used in domestic and foreign medical institutions, judicial testing systems, and third parties. Testing institutions, disease prevention and control centers, blood collection stations, private clinics, etc.
The company’s main products are developed based on the preparation and labeling technology of colloidal gold/latex/fluorescent particles, immunochromatography technology, monoclonal antibody technology, etc. Compared with traditional diagnostic methods, they have strong specificity, high sensitivity, it is simple, fast, and cost-effective. Generally does not require special equipment, and suitable for large-scale screening. At the same time, Biotest continues to invest in molecular diagnostic technology platform and animal disease detection service platform related technology reserves, as a strategic technology platform, laying the foundation for continuous business technology innovation in the future.
The company has 134 patented technologies at home and abroad, including 113 domestic patents (including 5 invention patents) and 21 overseas patents (including 1 invention patent); the company also owns 2 domestic software copyrights. Biotest 's products have obtained relevant registration certificates in more than 30 countries and regions including Asia, North America, Europe, South America, and Africa, and the products are sold all over the world.
In 2015, Hangzhou Biotest Biotech Co., Ltd completed the acquisition of Advin Biotechnology Co., Ltd. of the United States. With the technology and talent advantages of the Silicon Valley of the United States, and adhering to the strategy of global research and development, Biotest not only established to provide innovative, timely, high-quality products for the global market, but also offering solution program and development center.
Please fill in your contact information
and your needs